[
  {
    "section": "section:1",
    "title": "A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer"
  },
  {
    "section": "section:2",
    "title": "PATIENTS AND METHODS"
  },
  {
    "section": "section:3",
    "title": "Patients"
  },
  {
    "section": "section:3",
    "title": "Study Design and Treatments"
  },
  {
    "section": "section:3",
    "title": "Efficacy"
  },
  {
    "section": "section:3",
    "title": "Safety and Tolerability"
  },
  {
    "section": "section:3",
    "title": "Pharmacokinetics"
  },
  {
    "section": "section:3",
    "title": "Tumor Biomarkers"
  },
  {
    "section": "section:3",
    "title": "Plasma Biomarkers"
  },
  {
    "section": "section:2",
    "title": "RESULTS"
  },
  {
    "section": "section:3",
    "title": "Patient Characteristics"
  },
  {
    "section": "section:3",
    "title": "Efficacy"
  },
  {
    "section": "section:3",
    "title": "Safety"
  },
  {
    "section": "section:3",
    "title": "Pharmacokinetic Results"
  },
  {
    "section": "section:3",
    "title": "Tumor Biomarkers"
  },
  {
    "section": "section:3",
    "title": "Blood Biomarkers"
  },
  {
    "section": "section:2",
    "title": "DISCUSSION"
  },
  {
    "section": "section:2",
    "title": "ACKNOWLEDGMENTS"
  },
  {
    "section": "section:2",
    "title": "REFERENCES"
  }
]